Search Results for keywords:"aggregate production quotas"

Found 2 results

Search Results: keywords:"aggregate production quotas"

💰 Only
Oldest Newest
  • 2024-30019 — Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024
    Type:Notice
    Citation:89 FR 102638
    Reading Time:about 10 minutes

    The Drug Enforcement Administration (DEA) has issued a final order establishing the adjusted 2024 aggregate production quotas for Schedule I and II controlled substances under the Controlled Substances Act, and the annual needs for certain list I chemicals like ephedrine. This decision was made after considering public comments and relevant factors such as production needs, diversion risks, and quotas set in prior years. DEA strives to ensure that these quotas meet lawful medical and scientific needs while preventing drug misuse. Some public suggestions, like changes to the procurement quota processes or addressing opioid shortage concerns, were noted but found to be outside the scope of this specific order.

    Simple Explanation

    The DEA made a plan for how much of certain strong medicines (like painkillers) can be made next year to make sure doctors have enough but not so much that they can be easily misused. They listened to people’s suggestions but didn’t make changes to some parts because it wasn’t part of this plan.

  • 2024-30023 — Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025
    Type:Notice
    Citation:89 FR 102649
    Reading Time:about 19 minutes

    The Drug Enforcement Administration (DEA), part of the Department of Justice, has issued a final order establishing the aggregate production quotas for controlled substances in schedules I and II, and the annual needs for chemicals like ephedrine and pseudoephedrine for 2025. The order responds to public comments, particularly concerns about potential drug shortages, emphasizing that DEA aims to balance preventing drug misuse with ensuring adequate supply for medical and scientific needs. The quotas are set to address legitimate needs while considering factors like past usage data and potential diversion risks. Public concerns about opioid shortages were discussed, with the DEA noting that various external factors could affect drug availability and reassured that they are working with other agencies to mitigate such issues.

    Simple Explanation

    The government set rules about how much of certain strong medicines can be made each year to make sure there's enough for people who need them, but they also want to stop people from using them in the wrong way. They listen to people’s worries about not having enough medicine but try to make sure there's a good balance.